Pharmaceuticals

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast to Reach $26.37 Billion by 2029, Driven by CAGR

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Sector?#_x000D_

In recent years, there has been a slight decrease in the size of the endocrinology drugs market. However, it is projected to expand from “$26.29 billion in 2024 to $26.2 billion in 2025, experiencing a compound annual growth rate (CAGR) of -0.3%. This growth during the historic period can be attributed to the rising prevalence of diabetes globally, enhanced government measures, increasing spending on healthcare services, growth in the incidence of adrenal gland disorders, increased demand for insulin analogs, and a rise in the number of endocrinologists._x000D_

_x000D_

The market for endocrinology drugs is anticipated to experience fractional growth over the subsequent years. It is projected to escalate to “$26.37 billion in 2029 with a compound annual growth rate (CAGR) of 0.2%. ” Factors such as a surging population with diabetes, increased occurrence of endocrine diseases, a rise in adolescents struggling from hormonal imbalances, and escalating rates of obesity will contribute to the market growth in the said forecast period. Some trending developments within this time frame will be technological enhancements, the uptake of advanced drug delivery modules, the incorporation of digital healthcare solutions, precision medicine, and combined therapies._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20769&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?#_x000D_

The upward trend in attention-deficit hyperactivity disorder (ADHD) cases is anticipated to fuel the development of the ADHD therapeutics market. The surge in ADHD cases denotes an increase in the number of diagnosed patients over time. ADHD treatment strategies focus on addressing the multifaceted aspects of this neurodevelopmental disorder, with the goal of enhancing symptom control, minimizing functional impairment, and enriching the lives of those with ADHD. For example, in a report released by the US-based publishing company, the Guardian, in January 2023, it was estimated that about 170,000 known patients were receiving treatment for ADHD in 2022, marking a 20.4% growth from the 141,000 known patients in the same period in 2021. Thus, the escalating occurrence of ADHD is propelling the expansion of the attention-deficit hyperactivity disorder (ADHD) therapeutic market._x000D_

_x000D_

The endocrinology drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Indication: Hyperthyroidism, Hypothyroidism, Diabetes, Polycystic Ovarian Syndrome, Growth Hormone Disorders, Pituitary Gland Disorders, Other Indications_x000D_

2) By Therapy Area: Diabetes Drugs, Thyroid Hormone Disorder Drugs, Human Growth Hormone, Testosterone Replacement Therapy, Others Therapy Areas_x000D_

3) By Distribution Channel: Hospital pharmacies, Online Pharmacies, Retail pharmacies_x000D_

4) By End User: Hospitals, Ambulatory Surgical Centers, Others End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Hyperthyroidism: Antithyroid Medications, Radioactive Iodine Therapy, Beta Blockers _x000D_

2) By Hypothyroidism: Levothyroxine-based Medications, Liothyronine-based Medications, Combination Hormonal Therapies _x000D_

3) By Diabetes: Insulin Therapies, Oral Antidiabetic Drugs (OADs), GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors _x000D_

4) By Polycystic Ovarian Syndrome (PCOS): Oral Contraceptives, Metformin, Clomiphene Citrate, Anti-Androgens _x000D_

5) By Growth Hormone Disorders: Recombinant Human Growth Hormone (rhGH), Growth Hormone Secretagogues, Growth Hormone Receptor Antagonists _x000D_

6) By Pituitary Gland Disorders: Somatostatin Analogs, Gonadotropins, Dopamine Agonists _x000D_

7) By Other Indications: Adrenal Gland Disorders, Osteoporosis, Parathyroid Disorders, Male Hormonal Imbalances _x000D_

_x000D_

#How Are Key Trends Driving Expansion In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?#_x000D_

Leading firms in the endocrinology drugs market are emphasizing the development of innovative products including ready-to-use vials, enhancing the process of administering medication. These vials, which are pre-dosed and pre-filled, do not require any preparation or reconstitution prior to administration. In December 2022, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, introduced a Levothyroxine sodium injection packaged in ready-to-use vials with a concentration of 100 mcg/mL. This formulation, designed for immediate application, eliminates the necessity of reconstitution and decreases the likelihood of making errors during preparation, thereby enhancing patient safety. It provides accurate and consistent dosing, which is vital for the management of conditions such as hypothyroidism and myxedema coma. Furthermore, these ready-to-use vials enhance the efficiency of healthcare providers by saving time and enabling precise administration in high-pressure healthcare situations._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry?#_x000D_

Major companies operating in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/endocrinology-drugs-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?#_x000D_

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrinology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20769&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_